Silodosin Production Cost Reports

The report provides detailed analysis essential for establishing a silodosin production plant. It encompasses all critical aspects necessary for silodosin production, including the cost of silodosin production, silodosin plant cost, silodosin production costs, and the overall silodosin production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a silodosin production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Silodosin Market Analysis: Demand and Supply Analysis, and Sourcing

Silodosin is a selective alpha-1A adrenoceptor antagonist used to treat benign prostatic hyperplasia (BPH). Kissei markets it as Urief, Recordati sells it under the Silodyx and Urorec brands, and Rapaflo was its US brand. Its molecular formula is C25H32F3N3O4, its molecular weight is 495.53, and its CAS number is 160970-54-7. Buyers can source it from API manufacturers, contract development and manufacturing organizations (CDMOs), intermediate suppliers, and finished capsule producers. Contract options include annual API supply, spot purchases, dual sourcing, and toll manufacturing of the alkylation or amidation step.

Silodosin has one labeled use, which involves treating the signs and symptoms of benign prostatic hyperplasia in adults. The recommended dose is 8 mg once daily with a meal, reduced to 4 mg once daily for patients with moderate renal impairment. At 8 mg per day, annual API consumption is 2.92 g per patient. One kilogram can cover approximately 342 patient-years, while 100 kg can cover about 34,247 patient-years. At the 4 mg daily dose, one kilogram can cover approximately 685 patient-years. Lupin's generic capsules have an AB rating to Rapaflo, and Novadoz also markets a generic version. DrugPatentWatch lists 14 applicants, while Drugs.com lists both Rapaflo strengths as discontinued.

Silodosin has a broad base of listed API suppliers. PharmaCompass reports 72 API suppliers, 16 US DMFs, 12 EU written confirmations, and 11 Korean DMFs for the product. Pharmaoffer lists 25 suppliers across 10 countries, including 11 in India, 6 in China, and one each in the Czech Republic, Germany, Japan, Jordan, South Korea, Slovenia, Spain, and the US. Ten suppliers hold US DMFs: ALP Pharm, AXXO, Hetero, Olon, Sichuan Qingmu, Sinoway, Torrent, Veranova, Zhejiang Huahai Zhicheng, and Zydus Cadila. Pharmaoffer lists Duke Chem and Hetero as inactive. A silodosin demand and supply analysis should consider DMF coverage, benzoate amine availability, dialkyl impurity control, and generic capsule uptake. Upon receipt, buyers check the assay, related substances, residual solvents, and crystalline form.

Summary of the Product, Grades, and Uses

Silodosin is an indoline carboxamide with a hydroxypropyl chain attached to the ring nitrogen and a trifluoroethoxyphenoxyethyl amino side chain. It has one stereocenter with an R configuration. The API appears as a white to pale yellowish-white powder with a melting point of about 105 to 109 degree Celsius. It is very soluble in acetic acid, freely soluble in alcohol, and very slightly soluble in water.

The impurity profile is an important factor in product quality. The Kissei manufacturing route produces a dialkylated by-product at 13.6% in the crude alkylation product, which is reduced to 0.9% through oxalate crystallization. A Mankind patent reports 1.83% to 3.2% of the N,N-dialkyl impurity in crude silodosin, which falls below 0.03% after salt purification. The example achieves 99.65% HPLC purity, exceeding the target of 99.5% or higher. Recrystallization from ethyl acetate produces the final solid.

The market covers five main product grade families. GMP-grade silodosin API with a US DMF serves capsule manufacturers, while intermediates such as benzoate amine tartrate and monooxalate support process development and manufacturing teams. Reference standards for related substances and research-grade solids are used in laboratories. Finished capsules are available as white, opaque hard gelatin capsules, with 4 mg capsules in size 3 and 8 mg capsules in size 1. The capsule fill contains D-mannitol, pregelatinized starch, magnesium stearate, and sodium lauryl sulfate. Novadoz packages 4 mg capsules in bottles of 30 and 8 mg capsules in bottles of 30 and 90. Capsules should be stored at 25 degree Celsius, with permitted excursions from 15 to 30 degree Celsius, and protected from light and moisture.

Main End-Uses of Silodosin

Silodosin is used to treat the signs and symptoms of benign prostatic hyperplasia. The recommended dose is 8 mg once daily with a meal, reduced to 4 mg for patients with creatinine clearance of 30 to 50 mL per minute. Its use is contraindicated in patients with creatinine clearance below 30 mL per minute or Child-Pugh scores above 10.

Silodosin has an absolute bioavailability of about 32%, protein binding of about 97%, a volume of distribution of 49.5 L, and an intravenous clearance of about 10 L per hour. Its half-life at steady state is 13.3 hours. Over 10 days, a radiolabeled dose is recovered at 33.5% in urine and 54.9% in feces. Glucuronidation by UGT2B7 produces KMD-3213G, which has a half-life of about 24 hours and an AUC approximately four times that of silodosin. Alcohol and aldehyde dehydrogenases produce KMD-3293, while CYP3A4 contributes a third metabolic pathway.

In 12-week placebo-controlled trials involving 466 patients receiving silodosin and 457 receiving placebo, retrograde ejaculation occurred in 28.1% of patients in the silodosin group compared with 0.9% in the placebo group. Dizziness occurred in 3.2% versus 1.1%, diarrhea in 2.6% versus 1.3%, orthostatic hypotension in 2.6% versus 1.5%, and headache in 2.4% versus 0.9%, respectively. Nasopharyngitis occurred in 2.4% versus 2.2%, while nasal congestion occurred in 2.1% versus 0.2%. The product labeling also includes a warning about intraoperative floppy iris syndrome.

Silodosin Market Risks

Silodosin faces lifecycle risks from generic competition. DrugPatentWatch reports that its core US exclusivity has ended, while Drugs.com lists both Rapaflo strengths as discontinued. Competition now comes from generic capsule manufacturers, including Lupin, Novadoz, and others. This price pressure on finished capsules also affects API prices, as PharmaCompass lists 72 silodosin suppliers.

Process selectivity is a major manufacturing risk. According to the Kissei patent, alkylation of the benzoate amine with the mesylate produces a dialkylated by-product at 5% to 20% in the crude product. The Mankind patent reports a dimer content of about 9% to 11% in an application. Oxalate crystallization adds salt formation and a hydrolysis step. The Sandoz patent identifies excessive alkylation in earlier methods as a cause of low yields and replaces this approach with reductive amination. However, this route requires sodium cyanoborohydride and a four-step aldehyde sequence, adding cost and complexity.

Reagent hazards also create solvent handling and safety risks. Amidation uses 30% hydrogen peroxide in DMSO with sodium hydroxide, making peroxide control and DMSO recovery important. When scaled to the patent ratios, DMSO consumption reaches 16.7 L per kilogram of API. Supply risk is linked to the concentration of manufacturers in a few countries. India accounts for 11 of the 25 suppliers listed by Pharmaoffer, while China accounts for 6. Four Chinese companies hold US DMFs. Duke Chem and Hetero are listed as inactive.

Silodosin Production Process and Main Cost Drivers

The silodosin production process runs from the benzoate amine tartrate through alkylation, oxalate purification, ester hydrolysis, and peroxide amidation to silodosin.

1. By Alkylation, Oxalate Purification and Peroxide Amidation: The main inputs are the benzoate amine tartrate, a trifluoroethoxyphenoxyethyl mesylate, sodium carbonate, tert-butanol, oxalic acid, potassium hydroxide, methanol, DMSO, hydrogen peroxide, sodium hydroxide & ethyl acetate.

Silodosin production by this route starts with the benzoate amine tartrate. Aqueous potassium carbonate frees the amine in ethyl acetate at room temperature over 2 hours. The free amine then reacts with 1.2 equivalents of the mesylate and sodium carbonate in anhydrous tert-butanol at reflux for 24 hours. Crude product reaches 6.40 g from 5.0 g of tartrate and carries 13.6% of the dialkylated by-product.

Oxalate crystallization purifies the crude. Oxalic acid dihydrate at 0.98 equivalents in isopropyl alcohol, with seeding and overnight standing, gives 5.43 g of the monooxalate and drops the by-product to 0.9%. That equals about 83% molar yield on the amine at the stated formula. Aqueous potassium hydroxide in methanol then removes the benzoate at room temperature overnight.

Amidation completes the synthesis. The nitrile alcohol is dissolved in DMSO with 5 N sodium hydroxide, and 30% hydrogen peroxide is added at or below 25 degrees Celsius. The mixture is stirred at 20 to 25 degree Celsius for 5 hours to convert the nitrile into the carboxamide. Sodium sulfite is then added to quench the peroxide. Acid-base extraction, followed by crystallization from ethyl acetate, produces 4.49 g of silodosin from 6.00 g of nitrile, corresponding to a molar yield of 72.1%.

A Mankind patent runs the same bond sequence with a phase transfer catalyst. Dipotassium hydrogen phosphate and tetrabutylammonium iodide drive the condensation in toluene or DMSO at 85 to 90 degree Celsius for 10 to 12 hours. Intermediate steps skip purification. Oxalate formation cuts the N,N-dialkyl impurity from 1.83% to 3.2% down to under 0.03%, and ethyl acetate recrystallization gives 99.65% HPLC purity.

Sandoz describes reductive amination as an alternative. The benzoate amine at 0.027 mol reacts with 1.19 equivalents of an aldehyde and 1.48 equivalents of sodium cyanoborohydride in methanol with acetic acid. The aldehyde comes from 2-methoxyphenol in four steps. Trifluoroethyl iodide at 4 equivalents with potassium carbonate in NMP at 120 degree Celsius for 10 hours gives the ether at 94% GC purity. Boron tribromide in dichloromethane below -10 degree Celsius removes the methyl group at 95% GC purity. Alkylation with bromoacetaldehyde, ethylene glycol acetal, and acid hydrolysis in dioxane and water at 95 to 100 degree Celsius gives the aldehyde at 98% GC purity.

A second Mankind patent builds the indoline from indoline itself. N-alkylation with bromochloropropane or dibromopropane, Vilsmeier-Haack formylation at C-5, nitroethane condensation, a second formylation at C-7, oxime formation, and cyanation in THF lead to the haloalkyl intermediate. Benzoate displacement and palladium reduction of the nitro group follow.

The drug product follows. Capsule fill combines API with D-mannitol, pregelatinized starch, magnesium stearate, and sodium lauryl sulfate in white opaque gelatin shells with titanium dioxide. Printing uses yellow iron oxide and a blue aluminum lake ink. Main levers on cost are the benzoate amine price, the mesylate price, the dialkyl by-product, oxalate yield, DMSO and peroxide handling, and solvent recovery.

Main Factors Affecting Silodosin Production Cost

Silodosin production costs begin with the benzoate amine core. At full stoichiometry, producing 1 kg of API requires 2.02 mol of silodosin, equivalent to 733 g of the amine as a free base or 1,036 g as tartrate. The mesylate, used at 1.2 equivalents, adds another 761 g.

Yield significantly affects raw material requirements. The two measured steps achieve yields of 83% for alkylation with oxalate isolation and 72.1% for amidation, giving a combined yield of about 60%. At a working yield of 59.9%, producing 1 kg of API requires 3.37 mol of amine, equivalent to 1,225 g as a free base or 1,731 g as tartrate, along with 1,271 g of mesylate. Since hydrolysis yield is reported only by mass, the actual overall process yield is lower.

Amidation determines much of the solvent and reagent consumption. At a yield of 72.1%, producing 1 kg of silodosin requires 2.80 mol of nitrile alcohol, equivalent to 1,336 g. Based on the patent ratios, this also requires 586 mL of 30% hydrogen peroxide, 1,002 mL of 5 N sodium hydroxide, 16.7 L of DMSO, and 468 g of sodium sulfite per kilogram of API. DMSO recovery therefore plays an important role in controlling production costs.

Capsule production adds another stage to the cost calculation. One kilogram of API can produce approximately 125,000 capsules of 8 mg or 250,000 capsules of 4 mg.

Variable costs include benzoate amine tartrate, mesylate, sodium carbonate, oxalic acid, potassium hydroxide, hydrogen peroxide, sodium hydroxide, and sodium sulfite. Solvents such as tert-butanol, isopropyl alcohol, methanol, DMSO, and ethyl acetate also contribute to costs. Utility expenses include steam, chilled water, nitrogen, electricity, and effluent treatment. Fixed costs cover glass-lined reactors, filters, centrifuges, dryers, solvent recovery systems, an encapsulation line, and quality control laboratories.

Raw Materials for Silodosin Production Plant and its Procurement

Raw material sourcing for silodosin mainly depends on benzoate amine and mesylate. The Kissei, Sandoz, and Mankind patents all start with the same benzoate amine, which Kissei uses in the form of R tartrate. The mesylate supplies the trifluoroethoxyphenoxyethyl side chain. Manufacturers producing this side chain start with 2-methoxyphenol or catechol, trifluoroethyl iodide, and bromoacetaldehyde ethylene glycol acetal.

The required reagents include sodium carbonate, potassium carbonate, oxalic acid dihydrate, potassium hydroxide, hydrogen peroxide, sodium hydroxide, sodium sulfite, sodium cyanoborohydride, boron tribromide, tetrabutylammonium iodide, and dipotassium hydrogen phosphate. Solvents include tert-butanol, isopropyl alcohol, methanol, ethyl acetate, DMSO, toluene, NMP, dioxane, and dichloromethane. Capsule production requires D-mannitol, pregelatinized starch, magnesium stearate, sodium lauryl sulfate, gelatin shells, titanium dioxide, and iron oxides. Packaging materials include bottles in sizes of 30 and 90 capsules, closures, and cartons.

Procurement begins with clearly defined specifications. Buyers establish requirements for API assay, chiral purity, related substances, and residual solvents. Starting material specifications cover assay, water content, and benzoate content. Supplier documentation includes certificates of analysis, the route of synthesis, safety data sheets, audit status, and DMF letters. Incoming material checks cover identity, assay, dialkyl impurities, and residual solvents.

Sustainability and Regulatory Requirements

Silodosin manufacturing raises sustainability concerns related to DMSO, peroxide, halogenated solvents, boron waste, and trifluoroethyl reagents. Dichloromethane, toluene, methanol, and NMP are classified as ICH Q3C Class 2 solvents, so specific residual limits apply to each.

Regulatory requirements depend on the dossier. The US label identifies Allergan USA as the distributor under license from Kissei, while Recordati Ireland holds the European authorizations for Silodyx and Urorec. PharmaCompass lists 16 US DMFs, 12 EU written confirmations, and 11 Korean DMFs. Product specifications limit the N,N-dialkyl impurity to below 0.03%, as reported by Mankind, while other individual impurities must remain below 0.1%. Plant documentation includes batch records, certificates of analysis, specification sheets, stability data, and change logs.

CAPEX and OPEX for a Silodosin Production Plant

A silodosin manufacturing plant is a small-molecule API facility with alkylation, salt purification, hydrolysis, amidation, and crystallization stages. Plant investment starts with receiving and storing benzoate amine tartrate, mesylate, oxalic acid, hydrogen peroxide, and solvents. Glass-lined reactors with reflux condensers handle the 24-hour tert-butanol alkylation process. Crystallizers and filters separate the oxalate, while hydrolysis reactors operate at room temperature. An amidation reactor holds DMSO and uses controlled peroxide dosing below 25 degree Celsius. Extraction vessels, crystallizers, centrifuges, and dryers recover silodosin from ethyl acetate. Solvent recovery columns handle DMSO, tert-butanol, isopropyl alcohol, and ethyl acetate streams. Capsule production requires a blender, an encapsulation machine, and a bottle-packing line. An effluent treatment unit and a QC laboratory equipped for HPLC, residual solvent, and impurity testing complete the plant. Civil infrastructure includes a process hall, laboratory block, utility yard, and warehouse.

Silodosin operating costs depend on the same inputs and process controls. Benzoate amine, mesylate, hydrogen peroxide, and solvents account for major variable costs, along with steam, chilled water, nitrogen, power, labor, testing, and freight. The production route, impurity control requirements, DMSO recovery, and capsule production scope determine the silodosin plant setup cost. The cost per kilogram depends on process yields, losses from dialkyl by-products, peroxide consumption, and solvent losses. Labor costs cover operators, shift supervisors, QC analysts, and safety officers, while maintenance covers reactors, dryers, filling equipment, and instruments.

Plant Location and Investment Factors

A workable silodosin site sits near chiral amine and side chain supply, with solvent supply, steam, power, port links, and effluent capacity. Selection criteria include permits for peroxide and DMSO, solvent recovery approvals, intermediate logistics, and export links. Listed producers sit in Matsumoto, Ahmedabad, Devens, and Cork, with Olon in Italy and KRKA in Slovenia. Buyers audit sites, so a prior FDA or EU GMP record shortens approval. PharmaCompass records 52 FDA inspections for Olon, 63 for Zydus and 45 for Veranova.

For a silodosin plant, the main investment decision is the route. Kissei documents alkylation with oxalate purification, Mankind adds a phase transfer catalyst to cut impurity carryover, and Sandoz replaces alkylation with reductive amination. Scope is a second decision: API only or API plus capsules. New entrants could assess tolling with an established maker, or buying the benzoate amine tartrate. Investment checks cover intermediate contracts, DMF timelines, peroxide safety approvals, customer audits & working capital.

Major Silodosin Producing Regions

India anchors silodosin API listings, with 11 of 25 Pharmaoffer suppliers. They include Zydus Cadila, Torrent, Hetero, IPCA, Olon Active Pharmaceutical and Lewens Labs. China follows with six suppliers, namely ALP Pharm, Sichuan Qingmu, Sinoway, Zhejiang Huahai Zhicheng, Zhejiang Tianyu & Easton. Europe hosts KRKA in Slovenia, AXXO in Germany, Veeprho in the Czech Republic, and Duke Chem in Spain. Japan hosts Kissei and Fuji Chemical, and the US hosts Veranova.

Demand centers on the US, Europe, Canada, Australia, and South Africa. PharmaCompass records 117 approvals in Europe, 8 in Canada, 4 in Australia, and 8 in South Africa.

Key Silodosin Producers

Kissei Pharmaceutical

• Originator of silodosin, sold as Urief.
• Matsumoto, Nagano company founded on 9 August 1946.
• Licenses the US product, distributed by Allergan USA.
• Holds a patent on benzoate amine alkylation and oxalate purification.

Recordati

• Holds the European authorizations through Recordati Ireland Ltd in Cork.
• Markets Silodyx and Urorec as 4 mg and 8 mg capsules.
• Both brands carry an authorization dated 29 January 2010.
• Also lists Silodosin Recordati as a generic version.

Olon

• Italian API group profiled at PharmaCompass as Olon.
• Lists 389 APIs, 159 US DMFs and 100 CEP or COS certificates.
• Records 52 FDA inspections.
• Pharmaoffer lists Olon Active Pharmaceutical as a silodosin supplier with a US DMF.

KRKA

• Slovenian maker listed at PharmaCompass as Krka.
• Lists 51 APIs, 7 US DMFs and 44 CEP or COS certificates.
• Holds 2 FDA inspections and 3 EDQM GMP registrations.
• Appears among silodosin suppliers at Pharmaoffer.

Zydus Lifesciences

• Ahmedabad-based maker, also listed as Zydus Cadila.
• Lists 359 APIs, 213 US DMFs, and 56 CEP or COS certificates.
• Records 63 FDA inspections and 28 WHO-GMP certificates.
• Holds a US DMF for silodosin at Pharmaoffer.

Veranova

• Devens, Massachusetts API maker, with Macfarlan Smith Limited trading as Veranova in the UK.
• Lists 92 APIs, 48 US DMFs, and 23 CEP or COS certificates.
• Records 45 FDA inspections.
• Holds a US DMF for silodosin at Pharmaoffer.